Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0019204 (
hepatocellular carcinoma
)
71,386
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Cytoplasmic polyadenylation element-binding protein 3
(
CPEB3
) is a sequence-specific RNA-binding protein. We had reported that
CPEB3
is involved in
hepatocellular carcinoma
(
HCC
) progression. However, the underlying mechanisms of
CPEB3
in
HCC
remain unclear. In this study, we firstly performed RNA immunoprecipitation to uncover the transcriptome-wide
CPEB3
-bound mRNAs (
CPEB3
binder) in
HCC
. Bioinformatic analysis indicates that
CPEB3
binders are closely related to cancer progression, especially
HCC
metastasis. Further studies confirmed that metadherin (MTDH) is a direct target of
CPEB3
.
CPEB3
can suppress the translation of MTDH mRNA in vivo and in vitro. Besides, luciferase assay demonstrated that
CPEB3
interacted with 3'-untranslated region of MTDH mRNA and inhibited its translation. Subsequently,
CPEB3
inhibited the epithelial-mesenchymal transition and metastasis of
HCC
cells through post-transcriptional regulation of MTDH. In addition, cpeb3 knockout mice are more susceptible to carcinogen-induced hepatocarcinogenesis and subsequent lung metastasis. Our results also indicated that
CPEB3
was a good prognosis marker, which is downregulated in
HCC
tissue. In conclusion, our results demonstrated that
CPEB3
played an important role in
HCC
progression and targeting
CPEB3
-mediated mRNA translation might be a favorable therapeutic approach.
...
PMID:CPEB3-mediated MTDH mRNA translational suppression restrains hepatocellular carcinoma progression. 3296 53